The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

The weight-loss drug eloralintide shows up to 20% body weight reduction in trial, offering hope for obesity treatment beyond ...

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, ...

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.

The daily pill may provide a more convenient alternative to injections, which patients can find difficult to administer.

Popular weight loss shots carry significant risk for some patients and doctors often fail to discuss those risks with ...

A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

The demand for weight-loss drugs like Ozempic and Zepbound is higher than ever, so much so that drugmakers Novo Nordisk and Eli Lilly are planning huge expansions in central North Carolina to meet the ...

A possible workaround came from a team led by Ernie Blevins of the University of Washington. They gave obese rats a low dose ...